Hemispherx Vows To Fight FDA’s Second Rejection Of Ampligen
This article was originally published in The Pink Sheet Daily
In a “complete response” letter, FDA requested at least one new clinical trial, along with nonclinical studies and numerous data analyses, before approval of the chronic fatigue syndrome drug. Hemispherx continues to assert the existing data support approval and plans an appeal to FDA’s Office of New Drugs.
You may also be interested in...
Clinical trial efficacy endpoints for investigational CFS/ME drugs should include patient-reported symptoms, but FDA is open to the use of instruments evaluated in other populations for this purpose, agency says in a new draft guidance.
December’s Arthritis Advisory Committee review of Hemispherx’s drug provided FDA with the first public opportunity to explain in detail why the chronic fatigue syndrome drug, in development for almost 25 years, has not passed regulatory muster to date.
In review documents released ahead of a Dec. 20 advisory committee meeting, agency questions the validity of Hemispherx’s post-hoc efficacy analyses and raises concerns about adverse events and the reliability of the safety data.